AVALO THERAPEUTICS Business Summary

Avalo Therapeutics Inc. (AVTX) is a clinical-stage biotechnology firm primarily focused on developing targeted therapies for immune-mediated inflammatory diseases with significant unmet needs. The company operates through a research-and-development business model, generating potential future value through the clinical advancement, licensing, and eventual commercialization of its proprietary monoclonal antibody pipeline. Its primary business segment is centered on immunology, led by its flagship asset AVTX-009, a high-affinity anti-IL-1β monoclonal antibody currently in Phase 2 development for hidradenitis suppurativa (HS). Avalo competes in a high-stakes immunology market against established players and specialized biotechs such as MoonLake Immunotherapeutics, AbbVie, and Novartis. The company distinguishes itself by targeting the upstream IL-1β node to address neutrophil-driven abscesses and tunneling, positioning AVTX-009 as a potential best-in-class treatment compared to existing TNF and IL-17 inhibitors. The company is led by Chief Executive Officer Dr. Garry A. Neil, a veteran pharmaceutical executive with a pedigree that includes senior leadership roles at Johnson & Johnson and serving as Chairman of the Board for Arena Pharmaceuticals prior to its $6.7 billion acquisition by Pfizer. The executive team is supported by Chief Financial Officer Christopher Sullivan, formerly of Sucampo Pharmaceuticals, and Chief Business Officer Taylor Boyd, who joined in late 2025 to spearhead strategic partnerships. Avalo's board includes notable industry figures such as Kevin Lind and Dr. Rita Jain, reflecting a deep expertise in clinical strategy and capital markets. The firm is backed by prominent healthcare-focused institutional investors, including Commodore Capital, TCG Crossover, and RA Capital Management, providing the financial runway necessary to reach critical data readouts for its lead clinical programs.